Loading...
Loading...
SLRN| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 94.4M |
| Operating I/L | -94.4M |
| Other Income/Expense | -0.0M |
| Interest Income | 10.5M |
| Pretax | -83.9M |
| Income Tax Expense | -10.5M |
| Net Income/Loss | -83.9M |
Acelyrin, Inc. is a clinical biopharma company specializing in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate, izokibep, is a small protein therapeutic designed to inhibit IL-17A with high potency, currently in Phase 3 clinical trials for treating Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, and in Phase 2 clinical trials for Axial Spondyloarthritis. Additionally, Acelyrin is developing lonigutamab, a humanized IgG1 monoclonal antibody for thyroid eye disease, and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT for chronic urticaria.
